Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
06 mai 2024 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
07 juil. 2023 07h07 HE
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
20 avr. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
07 mars 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Global Non-Cancerous Blood Disease Market to Grow with a CAGR of 6.40% During 2022-2031 and Touch USD 105972.8 Million by 2031; Growing Prevalence of Anemia, Hemophilia, and Other Non-Cancerous Blood Diseases to Drive the Market Growth
06 avr. 2022 09h38 HE
|
Research Nester
New York, April 06, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) recently stated that around 80 Million people in the European Union (EU) were currently affected by blood...
Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.
04 janv. 2021 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced...
Arch Therapeutics, Inc. to Present at the Virtual Investor KOL Roundtable
22 oct. 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET
10 sept. 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET
26 août 2020 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...